How to Create and Grow a Successful Biotechnology Cluster

Transkript

www.gate2biotech.cz • www.hospimedica.cz
How to Create and Grow
a Successful Biotechnology Cluster
22. October 2008 • Brno, Czech Republic
3rd International Biotechnology Conference Gate2Biotech • How to Create and Grow a Successful Biotechnology Cluster
1
Welcome address
The Czech Republic does not have any big deposits of raw materials, and it has big problems maintaining a clean
environment. For that reason, all high-tech technologies that make no big demands on raw materials or energy, and,
at the same time, do not produce significant amounts of waste are ideal for the Czech Republic. Modern biotechnologies,
and cellular and gene engineering in particular, meet those criteria. It therefore comes as no surprise that biotechnologies
have for many years been among topics at the top on the priority list for public funding. Such topics do not include only
basic research projects in such fields as molecular genetics, immunology and others, but, especially, projects closely
linked to a practical implementation.
While basic – and oftentimes even applied – research is well established at Czech universities and in institutes of the
Academy of Sciences of the Czech Republic and is of high quality, the number of new themes for production in existing
undertakings, or for the establishment of new undertakings, remains insufficient. This is then reflected in the small
number of biotechnology companies and in unsatisfactory numbers of employees in this field, and in a low turnover
in general.
We are now facing a big challenge for the development of biotechnologies in the Czech Republic, which is the
implementation of the Operational Programme Research and Development for Innovations (OP RDI). A number
of institutions in the main biotechnology centres in Brno, Olomouc and in the Central Bohemian region near Prague
have joined forces to work on projects that may substantially boost the development of applied biotechnologies.
Research and development in biotechnology companies should be further promoted by the Operational Programme
Enterprise and Innovations (OP EI), which is coordinated by the Ministry of Industry and Trade of the Czech Republic.
We believe that all these programmes will substantially contribute to the establishment of new infrastructures and will
increase the volume of research, development and implementation of biotechnology products in the Czech Republic.
Doc. MUDr. Vladimír Viklický, CSc.
Director of the Radiopharmaceuticals Division of the Nuclear Research Institute Řež plc
3
Gate2Biotech Conference Programme
09:00–10:00
Registration & Coffee
Moderator: Jiří Krechl, Ph.D., Director of R&D Support Department, CzechInvest
SECTION 1:
Get Inspired by the Best Practices on Cluster Development from Abroad
Welcome and Opening: Miloň Polešák, Executive Manager for SME Clients at ČSOB
Mark S. Paller, M.D., M.S., Assistant Vice President for Research, Academic Health Center
and Professor of Medicine at the University of Minnesota (Rochester, Minnesota, U.S.A.):
Minnesota Partnership – Activities and Impact
Eric D. Wieben, M.D., Ph.D., Director, Mayo Genomics Research Center, Mayo Clinic (Rochester,
Minnesota, U.S.A.) & Co-Director, Minnesota Partnership for Biotechnology and Medical Genomics:
Building Scientific Partnership in Biotech Research between Minnesota and Brno – Challenges and Needs
11:05–11:35
Dr. Jeff Solomon, CEO, ERBI (Eastern Region Biotech Initiative), Cambridge, UK:
Cambridge and the East of England Biotech Cluster
11:35–12:05Robert David Kirk, Senior Lecturer, Centre for Enterprise Management,
University of Dundee, Scotland (UK): BioDundee
12:05–12:25
Questions & Discussion
12:25–13:30
Lunch & Discussion
10:00–10:05
10:05–10:35
10:35–11:05
SECTION 2:
Do the Key Czech Biotech Projects reflect the Global Trend?
13:30–13:35
13:35–13:55
13:55–14:15
14:15–14:35
14:35–14:55
14:55–15:55
Welcome and Opening
Tomáš Kára, M.D., PhD., Medical Director, International Clinical Research Center Brno (ICRC Brno):
ICRC Project Update
Prof. Jaroslav Koča, Masaryk University Brno: Central European Institute of Technology(CEITEC)
Project Update
Peter Šebo, PhD., Director, Institute of Biotechnology AS CR, v.v.i.: BIOCEV Project Update
Dr. Michal Kostka, South Moravian Innovation Centre:
Results of Regional Survey on Trends in Life Sciences
Questions & Discussion
Main Partner
Československá obchodní banka, a. s.
Československa obchodni banka, a. s. is a universal bank operating in the Czech Republic. ČSOB was established by
the state in 1964 as a bank to provide foreign trade financing and convertible currency operations. It was privatized
in June 1999 when KBC Bank, a member of Belgium’s KBC Group, became the majority owner. ČSOB took over Investicní
a Poštovní banka, a.s. in June 2000. ČSOB had been active in both Czech and Slovak markets until 2007; the Slovak branch
was separated as of 1 January 2008.
ČSOB’s business profile comprises the following segments: retail (individuals), SMEs, corporate and non-banking financial
institutions, financial markets and private banking. ČSOB is operating under two retail brands in the Czech Republic
– ČSOB and Poštovní spořitelna (Postal Savings Bank – PSB); the latter is using the wide distribution network of Czech
Post. To serve their clients, ČSOB has 227 branches in the Czech Republic while PSB has 32 Financial Centers and approx.
3,350 post offices (as at 30 June 2008). Both ČSOB and PSB also provide their services through various direct-banking
channels. In addition to its own products, ČSOB is distributing products and services of the whole ČSOB Group.
Along with its own products and services, ČSOB’s branch network offers products and services of the entire ČSOB
Group. Comprehensive service portfolio thus also includes insurance and pension products (ČSOB Pojišťovna and
the Stabilita and Progres pension funds), financing the housing needs (Hypotečni banka and Českomoravská stavební
spořitelna) collective investment and asset management (investment funds of ČSOB Investment company a ČSOB Asset
Management) and specialized services (ČSOB Leasing and ČSOB Factoring). Services related to trading on financial
markets are provided by Patria, a sister company of ČSOB.
The primary goal of the ČSOB Group is to build a strong, long-term partnership with each client by being a good listener
and offering suitable solutions, not just products, and providing clients with livelong advisory services in the areas
of personal and family needs, SME and corporate finance.
5
Enterprise Europe Network
“A one-stop shop for businesses in over 40 countries”
The Enterprise Europe Network is the largest network of contact points providing information and advice to EU
companies on EU matters, in particular small and medium enterprises (SMEs).
The network offers concrete and effective solutions to entrepreneurs and companies in more than 40 countries, including
the 27 EU member states, three EU candidate countries (Croatia, the former Yugoslav Republic of Macedonia and Turkey),
members of the European Economic Area (EEA) and other participating third countries.
Launched in 2008 by the European Commission, the Enterprise Europe Network combines and builds on the former
Innovation Relay Centres and Euro Info Centres (established in 1995 and 1987 respectively). The new integrated network
offers a “one-stop shop” to meet all the information needs of SMEs and companies in Europe.
Instruments include business partner search within technology and business cooperation databases and fast access
to information on funding opportunities, individual on-site visits to companies to assess their needs and a broad range
of promotion and information material. Representatives of the network can also help businesses understand EU law, how
it applies to their business and how to make the most the internal market and EU programmes.
The Enterprise Europe Network fully exploits the synergies between all support services and helpdesks aimed at
European businesses. The “one-stop shop” service is accompanied by a “no wrong door” policy: an entrepreneur or
business actor can enter the network through any contact point, and will then be assisted and personally directed to the
relevant service or organisation.
Business actors are encouraged to share, define and disseminate best practices in fields such as innovation, expansion
to new markets, enlargement of the client base, improvement of market position, etc. As a result, the Enterprise Europe
Network helps SMEs realise their potential in terms of growth and regional job creation.
Activities of the Czech Enterprise Europe Network are realized by a consortium of eleven project partners coordinated by
the Technology Centre of Academy of Sciences of the Czech Republic.
www.enterprise-europe-network.cz
The project is supported by the Competitiveness and Innovation Framework Programme (CIP)
Speakers Index
Mark S. Paller, M.D., M.S.
Dr. Mark S. Paller is Assistant Vice President for Research, Academic Health Center and
Professor of Medicine at the University of Minnesota. He oversees the Office of Clinical
Research, the Biomedical Genomics Center, the Molecular and Cellular Therapy Program,
Research Animal Resources, and all AHC intramural grant programs. He played a key role in
developing the research partnership between the University of Minnesota and Mayo Clinic,
the Minnesota Partnership for Biotechnology and Medical Genomics, which he co-directs.
Nationally, he was the founding chair of the Association of Academic Health Centers Vice
Presidents for Research Executive Leadership Group. Paller has extensive experience in
basic and translational research with more than 100 publications. His primary research
interest and area of expertise is the cell biology of acute renal failure.
Paller received his medical degree at Northwestern University, performed an internal
medicine residency at Case Western Reserve University and a nephrology fellowship
at the University of Colorado, and received a Master’s degree in Administrative Medicine
from the University of Wisconsin-Madison. He is a practicing nephrologist with interests in
chronic kidney disease, transplantation, pregnancy and kidney disease, and hypertension.
Eric D. Wieben
Dr. Wieben is the Director of Mayo Clinic Genomics Research Center and Professor of
Biochemistry and Molecular Biology at the College of Medicine-Mayo Clinic. He is also on
the Board of Directors of the BioBusiness Alliance of Minnesota.
As the son of an Army officer, Eric grew up in many locations including France, Japan, and
Senegal. He graduated from high school in Israel and began college at Tel Aviv University.
Dr. Wieben earned a B.S. degree in Biological Sciences with highest distinction from
Indiana University and a Ph.D. in Biology from Yale University. Dr. Wieben completed
his post doctoral fellowship at the Worcester Foundation for Experimental Biology
before joining the Department of Biochemistry and Molecular Biology at Mayo in 1983.
Dr. Wieben was Chair of the department for 7 years during a time when the department
was facing major challenges from the genomic revolution. In 2002 he became the
Director of the Genomics Research Center at Mayo and in 2003 he helped to establish the
Minnesota Partnership for Biotechnology and Medical Genomics, Mayo‘s public-private
collaboration with the University of Minnesota and the State of Minnesota.
Dr. Wieben’s current and primary research interest is in the area of pharmacogenomics.
He is collaborating with Dr. Richard Weinshilboum to determine how genes influence the
response of individuals to drug therapy. They are working to define the range of individual
genetic variation in the genes that code for drug metabolizing enzymes, and how that
variation can influence both the effectiveness of the drug and the likelihood of adverse
side effects.
7
Dr. Wieben has received many rewards and recognitions, including 5 patents and the
Mayo Foundation Distinguished Educator Award.
Jeff Solomon
Jeff graduated from University College London with a Ph.D. in biochemical engineering
and has over 25 years experience working with a variety of organizations within the
healthcare and life science sectors undertaking and managing R&D and developing
strategy. He joined the ERBI initiative and focused its efforts on the development of
networking and communications within the Cambridge and East of England biocommunity. In April 2000 ERBI became an independent not-for-profit company and
Jeff became its full time Chief Executive. In that time ERBI has grown to over 360 paying
members and ERBI has increased 10 fold in size. In January 2008 ERBI added activities
aimed specifically at the medtech community. Jeff has worked in Cambridge for 25
years and has experienced the growth of biotechnology in the region. In his spare time,
Jeff is a member of the Institute of Directors, an advisory board member for the Centre
for Integrated Photonics (CIP), sits on the advisory panel for UKTI’s Biotechnology and
Pharmaceutical Services and finally is the Chair of the Council of European Bioregions.
Robert David Kirk
David Kirk is the director of Masters Degree programmes in Spatial Planning at the
University of Dundee, Scotland. Upon graduating in 1972 from the University of Glasgow,
David followed a professional career in programme planning and project management
in a variety of public and private organisations in the UK, positions in which he was
principally involved in economic development. In 1993, he began a university career
and has led programmes in enterprise management and in spatial planning. David
collaborated with a number of technical universities and industrial firms in Poland during
the 1990’s for which he received the award of the Knights Cross from the Republic of
Poland in 2002. He has a number of published papers on innovation and knowledge
transfer. Over the last three years he was an active participant in the NetBioClue network
sharing knowledge about the processes required for developing biotech clusters.
Tomáš Kára
Tomáš Kára, MD, PhD is the Executive Director of the International Clinical Research Center
Brno project that will be constructed at St. Anne’s Hospital in Brno, Czech Republic and
Associate Professor of Medicine at Division of Cardiovascular Diseases at Mayo Clinic
and Mayo School of Medicine, Rochester, Minnesota. Dr. Kara’s main focus is clinical
cardiology and cardiovascular research, including development of new technologies for
cardiovascular diseases diagnostics and treatment.
Arnošt Marks
Arnost Marks (41) graduated from Charles University (Prague) with masters degree in
general biology in 1991 later he received PhD. degree on Knowledge and Technology
Management Transformation in Post Communist Countries from University of Cambridge
in 1997. Then he worked for Technology Centre of the Czech Academy of Sciences and as
a project manager he ran projects for technological companies on EU programmes. He
spent 8 years in public administration working for Deputy Chairman of Senate, Advisor
to the Ambassador of the EU in the Czech Republic and finally as a director general
responsible for managing implementation EU Funds in the Czech Republic 2004–2006 and
2007–2013 in the Ministry for Regional Development. Presently he represents project of
Central European Institute of Technology (CEITEC) in Brno as its executive director.
Peter Šebo
Dr. Peter Šebo worked for 6 years at CNRS and Institut Pasteur in Paris, before he returned
to the Institute of Microbiology in Prague in 1995. He is currently the director of the newly
founded Institute of Biotechnology and is in charge of preparing the construction of
a major research infrastructure for the Biotechnology Research Center of the Academy of
Sciences with Charles University (BIOCEV).
Jiří Hudeček
Jiří Hudeček is CEO of the South Moravian Innovation Centre, leading Czech organization
for support of innovative start-up companies. As an entrepreneur and manager with over
10 years of experience in senior positions, Jiří has worked for a number of institutions
including GE Capital Bank, LKW Walter International and others. He currently leads a team
of 20 professionals dedicated to support of innovative enterprises in the South Moravian
region through implementation of the Regional Innovation Strategy.
9
Internet portal www.gate2biotech.cz contains all information about
biotechnology in one place. The website is aimed at biotechnology
companies, suppliers, investors, institutions, students, professional
community and everyone interested in this field of future.
Gate2Biotech maps over all biotech news and its users can also
find a complete database of Czech biotechnology companies and
research entities. The database is searchable by their specialisation,
offers and request of collaboration or jobs, overview of currently
undertaken research projects, contains information on international
conferences, seminars, fairs and other interesting events. Through
the portal the companies can easily search partners for various
technology problem solutions and present their services to potential
partners from the Czech Republic and abroad. The users of the
website are located in more than 50 countries.
Internet portal www.inovace.cz aims to create a central place for
all Czech subjects interested in innovation by providing targeted
information, linking to other relevant services and assisting in
realisation of their innovative projects.
The website is aimed at researchers, inventors, innovative companies,
research institutions, investors and organisations supporting
innovations.
The content of the website comprises information on innovation
from the Czech Republic and abroad providing:
Information about funding and support innovative projects
Important contacts, supply and demand for cooperation
News and articles about trends in research and development
Calendar of events
Case Studies
Organization
International Clinical Research Center Brno (ICRC)
One of the European Union’s largest initiatives for the 21st century in the area of biotechnology and medical research will
be based on collaboration between the Mayo Clinic and the Czech Republic’s International Clinical Research Center (lCRC)
in Brno, Czech Republic. The ICRC partnership will focus on medical research and education, particularly in the areas of
cardiovascular and neurovascular diseases, internal medicine, neurology and oncology. The multifunctional centre will
offer advanced clinical research facilities, a state-of-the-art cardiovascular clinical centre, international educational centre
and a technology cluster. ICRC brings to Czech scientists new opportunities for international collaboration.
www.icrcbrno.org
St. Anne’s University Hospital
Pekařská 53
656 91 Brno
Tomáš Kára, M.D., Ph.D.
Executive Director, ICRC Brno
Tel.: +420 543 181 161
E-mail: [email protected]
11
The South Moravian Innovation Centre
The South Moravian Innovation Centre (JIC) creates a complex infrastructure for innovative enterprise in the South
Moravian region supporting innovative companies, science, research and development and students with original ideas.
JIC was established as an association of legal entities in 2003. Its founders are the South Moravian Regional authority, the
Statutory City of Brno, Masaryk University and Brno University of Technology. In February 2005 the group was joined by
Mendel University of Agriculture and Forestry and University of Veterinary and Pharmaceutical Sciences in Brno.
The services of the Centre are based on four key pillars:
finances
consultancy
contacts
premises
One of the main activities of the centre is operating the Technology Incubator at Brno University of Technology and the
Technology Incubator II of the South Moravian Regional Authority, which concentrate several support tools for starting
entrepreneurs in one place, reduce the risk for start-ups and assist them to achieve the level they could engage selfdependently in commercial-economic activities and compete on the market.
The South Moravian Innovation Centre is the coordinator of the Regional Innovation Strategy of the South Moravian
Region which is a strategy for increasing implementation and fostering innovation.
JIC is a member of the Enterprise Europe Network – the largest network of contact points providing information and
advice to EU companies on EU matters, in particular small and medium enterprises (SMEs).
The South Moravian Innovation created and operates 2 web portals: www.INOVACE.cz aims to create a central place for
all subjects interested in innovation by providing targeted information, linking to other relevant services and assisting
in realisation of their innovative projects, portal www.gate2biotech.cz, is the main guide-post and information umbrella
covering all biotech activities in the Czech Republic. In 2006 JIC published the first ever annual publication of detailed
information about Czech biotech sector “Czech Biotech Report”.
JIC, zajmove sdruzeni pravnickych osob
U Vodárny 2
616 00 Brno
Tel.: +420 541 143 000
Fax: +420 541 143 011
www: www.jic.cz
E-mail: [email protected]
List of Participants
1
Adámek Petr, Ing. MBA
Berman Group – služby ekonomického rozvoje, s.r.o.
2
Bažant Petr, Ing. CSc. MBA
Ústav experimentální medicíny AV ČR, v.v.i.
3
Bernatová Karolína
Vysoká škola Báňská
4
Bohrn Tomáš
ChipInvest a.s.
5
Bryndová Marta, Ing.
MZLU v Brně
6
Bula Daniel
7
Bunček Martin, RNDr., Ph.D.
GENERI BIOTECH s.r.o.
8
Cieslarová Jaroslava, Mgr.
MZLU Brno
9
Činčarová Lenka, Mgr
Masarykova Univerzita, PřF
10
Damborský Jiří, Dr.
Enantis s.r.o.
11
Dita Ilona
Biotechnologický ústav AV ČR, v.v.i.
12
Doležalová Anna
Výzkumný ústav bramborářský Havlíčkův Brod, s.r.o.
13
Domkářová Jaroslava
14
Fryč Jan
VŠB – TU Ostrava
15
Fusek Martin, Doc. Ing. CSc.
Life Sciences Capital s.r.o.
16
Greplová Marie
17
Grochová Diana, PhD.
Centrum prenatální diagnostiky, s.r.o.
18
Guňka Karel, Ing.
CONSULT
19
Hadam Jakub, Mgr.
Merck, s.r.o.
20
Havlíček Martin, Ing.
Ústav biomedicínského inženýrství VUT v Brně
21
Havránek Ivo
VŠB – TU Ostrava
22
Hejátko Jan
Masarykova Univerzita
23
Heřmánek Jiří, RNDr.,MBA
Genzyme Europe BV
24
Hettner Michal
Central European Biosystems s.r.o.
25
Hezinová Věra, Ing.
Ústav analytické chemie AV ČR, v.v.i.
26
Holub Petr, Mgr.
NCBR – Národní centrum pro výzkum biomolekul
27
Horna Aleš, Doc. Ing. CSc.
RADANAL
28
Hradil Ondřej, Ing.
Masarykova univerzita
29
Hrdličková Barbara
UPF LF, Masarykova Univerzita
30
Hudzieczek Vojtěch
MZLU Brno
31
Hutňan Ivan, Ing.
BIOHEM s.r.o.
32
Hutová Eliška
VUT v Brně
33
Chaloupka Jaroslav, Ing., PhD.
BIC Brno, Podnikatelské a inovační centrum
34
Chalupová Pavla, Ing.
MZLU v Brně
35
Chládek Petr, Mgr.
Regionální rozvojová agentura jižní Moravy
36
Chrást Lukáš
Masarykova Univerzita – PřF
37
Chroboková Eva
Zahradnická fakulta MZLU v Brně
38
Chromá Ludmila, Ing. PhD.
Bioveta, a.s.
39
Chroustovský Jiří
Worthald Partners
40
Jablonka Radim
VŠB – TU Ostrava
41
Janouškovcová Eva, RNDr., Ph.D.
42
Jaroš Josef, Ing.
43
Kalivodová Tereza, Ing.
Brain Logistics, s.r.o.
44
Kaplanová Kateřina, Ing.
MZLU v Brně
45
Klečková Zita, PhDr.
CEET s.r.o.
13
46
Kolář Vladimír, RNDr.
BioVendor – Laboratorní medicína a.s.
47
Koudelka Štěpán, Ing.
Výzkumný ústav veterinárního lékařství
48
Kowalczuková Barbora
ICRC Brno
49
Kramářová Gabriela, Bc.
British Embassy
50
Krejčí Jan, RNDr., PhD.
BVT Technologies a.s.
51
Krupková Olga, Bc.
52
Křepelka Jiří, Ing., CSc.
INVENTIA s.r.o
53
Kubešová Barbara, MUDr.
Tkáňová banka FN Brno
54
Kubešová Blanka
55
Kupská Eva, Ing.
VOP-026 Šternberk, s.p., divize VTÚO Brno
56
Lapka Roman, RNDr.
Zentiva a.s.
57
Lexa Jiří, Ing.
Centrum ekonomických studií VŠEM
58
Libra Antonín, Ph.D.
GENERI BIOTECH s.r.o
59
Linhart Jakub
Bioveta, a.s.
60
Lukáč Róbert, Mgr.
61
Maděránková Denisa, Ing.
VUT v Brně, FEKT, ÚBMI
62
Makyčová Michaela, Mgr.
Teva Pharmaceuticals CR, s.r.o.
63
Marková Michaela, RNDr.
Biofyzikální ústav AV ČR, v.v.i.
64
Mašek Josef, Mgr.
65
Mikeš Jiří, Ing.
EPS s.r.o.
66
Moudra Alena, Bc.
67
Mozga Tomáš, Mgr.
68
Mráčková Martina
Biofyzikální ústav AV ČR, v.v.i.
69
Mrázek Stanislav, MBA
CEITEC Cluster
70
Nadiradze Kakha
Biotechnology Center of Georgia
71
Nicodemou Andreas, Mgr.
BIOHEM s.r.o.
72
Novotná Zlatuše, MVDr.
73
Obruča Stanislav, Ing.
Fakulta chemická VUT v brně
74
Opletal Kamil
Mitsubishi Corporation
75
Partl Martin, Ing.
CzechInvest
76
Passe Jana
Passe Intellectual Property, LLC
77
Passe Jim
Passe Intellectual Property, LLC
78
Pavlík Adam
79
Petřík Theodor, Ing., CSc.
Shimadzu GmbH organizační složka
80
Pisko Michal, Ing., Ph.D.
ExPS s.r.o.
81
Pitthart Tomáš
Institut klinické a experimentální medicíny
82
Plchút Martin, Ing.
ANF Data
83
Plucar Bohumír, MUDr.
4 RESEARCH s.r.o.
84
Polzerová Hana
85
Proksa Bohumil, Ing. DrSc.
Zentiva a.s.
86
Prokšík Jan, Ing.
Ústav experimentální medicíny AV ČR, v.v.i.
87
Průchová Anna
88
Rajnoch Jan, MUDr.
Biotechnologický ústav AV ČR, v.v.i.
89
Rašková Petra, Ing.
Jihočeská agentura pro podporu inovačního podnikání o.p.s.
90
Rohrer Michal
MZLU v Brně
91
Roleček Jiří, Ing.
92
Rusek Jakub, Bc.
Masarykova Univerzita – PřF
93
Ružovič Tomáš
VŠB – TU Ostrava
94
Sára Petr, Mgr.
Pliva – Lachema Diagnostika s.r.o.
95
Seidl Petr
Genzyme Europe BV
96
Schůrek Lukáš
PrimeCell a.s.
97
Slovák Jan
98
Smejkal Petr
Ústav analytické chemie AV ČR, v.v.i.
99
Šrubařová Petra, Ing.
MZLU v Brně
100
Šurová Ivana
BioTest s.r.o.
101
Tesaříková Zuzana, Bc.
MZLU Brno
102
Tichá Olga
Fakultní nemocnice u svaté Anny
103
Tomanová Eva, Mgr.
CzechInvest
104
Tomko Jaroslav, Ing.
ZINCHEM, a.s.
105
Ungmanová Lenka, Ing.
Merck spol. s r.o.
106
Weisz Filip
MZLU v Brně
107
Zábský Jan
BioTest s.r.o.
108
Zimová Hana, Bc.
15
www.gate2biotech.cz • www.hospimedica.cz
main partner
2008/10
organisation

How to Create and Grow a Successful Biotechnology Cluster

Transkript

Podobné dokumenty

Quid pro quo in Brno

UMBL AJ

Brno Business Park Budova B

Development of the Waste management in the area of

AGT CE Belgesi ING

REFRA 2017 Abstract template v1 (2)

zde. - Brno

1st circular of the conference

1 circular

Czech Questions and Answers